Intestinal Epithelial Fucosylation Affects the Efficacy of Ustekinumab in Crohn's Disease
- Conditions
- IBD
- Registration Number
- NCT06203158
- Lead Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
- Brief Summary
The loss of response rate of ustekinumab(UST) is high, and the specific mechanism has not yet been elucidated. Molecular markers that can accurately predict the efficacy of UST are urgently needed to provide theoretical basis for guiding individualized treatment. Therefore, this study intends to explore the impact of intestinal epithelial fucosylation levels on the efficacy of UST in patients with Crohn's disease(CD), aiming to provide predictable molecular markers for UST to accurately treat CD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- Diagnosed with moderate to severe Crohn's disease
- Receiving treatment with ustekinumab
- Received colonoscopy and collected intestinal tissue samples before and after treatment
- Pregnancy
- Hypersensitivity to any component of ustekinumab
- Cognitive or developmental disabilities prevent you from completing this study
- Combined with diseases such as RA, diabetes, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis and tumors
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method clinical remission rate at 24 week at 24 week A specialist will evaluate the HBI score at 24 week based on the patient's clinical symptoms and determine whether the patient is in clinical remission based on the score.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Second Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China